title: Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.
abstract: Amyloid-beta (Aβ) in Alzheimer's disease (AD) appeared to be a promising target for disease-modifying therapeutic strategies like passive immunotherapy with anti-Aβ monoclonal antibodies (mAbs). Biochemical markers in cerebrospinal fluid (CSF) include alterations of Aβ that allow the diagnosis of AD. Biomarker strategies, such as the levels of Aβ in CSF and plasma, currently play an important role in early clinical trials for AD. Indeed, these strategies have a relevant impact on the outcome of such studies, since the biomarkers are used to monitor the bioactivity of anti-Aβ mAbs. The clinical trials of Solanezumab were mainly based on the readout of Aβ levels in CSF and plasma, whereas those of Bapineuzumab were based on cognition; however, little is known about the mechanisms altering these biomarker levels, and no biomarker has yet been proven to be a successful predictor for AD therapy. In addition, the Aβ biomarkers allow for the determination of free and bound anti-Aβ mAb in order to monitor the available amount of bioactive drug and could give hints to the mechanism of action. In this review, we discuss clinical Aβ biomarker data and the latest regulatory strategies.
authors.affiliation: Faculty for Biotechnology, Institute of Applied Biotechnology, Biberach University of Applied Science Biberach/Riss, Germany.
authors.forename: Jens
authors.initials: J
authors.lastname: Moreth
authors.forename: Chrystelle
authors.initials: C
authors.lastname: Mavoungou
authors.forename: Katharina
authors.initials: K
authors.lastname: Schindowski
keywords: CSF; dementia; mode of action; passive immunization; pharmacogenetics and pharmacogenomics; plasma increase; regulatory strategy; therapeutic monoclonal antibodies